TIGIT-mediated signaling is known to suppress an array of anti-cancer immune cells and has been associated with poor prognosis in a variety of tumor types.
A randomized Phase 3, open-label, study to evaluate the efficacy of zimberelimab (AB122) monotherapy compared to standard chemotherapy or zimberelimab combined with domvanalimab (AB154) in front-line, PD-L1-positive locally advanced or metastatic non-small cell lung cancer.
A Phase 2 trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab + zimberelimab, and domvanalimab + zimberelimab + etrumadenant in front-line non-small cell lung cancer.
A Phase 1b trial to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab ± zimberelimab in participants with advanced solid malignancies.
